-
AffaMed Technologies Secures Exclusive Rights to SIFI’s Intraocular Lens Products in Greater China
•
AffaMed Technologies, a joint venture between China’s AffaMed Therapeutics and Italy-based SIFI S.p.A., has announced a significant licensing agreement with the SIFI Group. This deal grants AffaMed exclusive rights to manufacture, develop, and commercialize SIFI’s range of intraocular lens (IOL) products in the Greater China region. The financial details of…
-
AffaMed Therapeutics’ Luminate Receives Clinical Trial Approval for Dry AMD in China
•
AffaMed Therapeutics, a China-based biotech firm, has announced the receipt of its first clinical trial approval in China for its pipeline candidate, Luminate (risuteganib; AM011). This development marks a significant milestone for the company, which acquired the Greater China manufacturing, development, and commercial rights to risuteganib from Hanmi Pharmaceutical, a…
